View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Aug. 03, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Trading Symbol	DVAX
Entity Registrant Name	DYNAVAX TECHNOLOGIES CORP
Entity Central Index Key	0001029142
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		38,403,449

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 36,486	$ 49,511
Marketable securities available-for-sale	56,895	73,141
Accounts receivable	657	727
Prepaid expenses and other current assets	3,858	4,058
Total current assets	97,896	127,437
Property and equipment, net	8,887	7,924
Goodwill	2,078	2,277
Restricted cash	613	632
Other assets	20	20
Total assets	109,494	138,290
Current liabilities:
Accounts payable	2,345	1,159
Accrued research and development	5,927	6,938
Accrued liabilities	4,746	6,317
Deferred revenues	7,448	5,865
Long-term debt, current portion	1,498
Total current liabilities	21,964	20,279
Deferred revenues, net of current portion	3,916	6,900
Long-term debt, net of current portion	7,961	9,559
Other long-term liabilities	1,125	1,070
Total liabilities	34,966	37,808
Commitments and contingencies
Stockholders’ equity:
Common stock: $0.001 par value; 69,500 shares authorized at June 30, 2015 and December 31, 2014; 30,237 and 26,307 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	30	26
Additional paid-in capital	719,966	695,058
Accumulated other comprehensive loss	(2,727)	(1,669)
Accumulated deficit	(642,741)	(592,933)
Total stockholders’ equity	74,528	100,482
Total liabilities and stockholders’ equity	109,494	138,290
Series B Convertible Preferred Stock
Stockholders’ equity:
Preferred stock: $0.001 par value: Authorized: 5,000 shares; Issued and outstanding Series B Convertible Preferred Stock — 17 shares at June 30, 2015 and 43 at December 31, 2014

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	69,500,000	69,500,000
Common stock, shares issued	30,237,147	26,307,000
Common stock, shares outstanding	30,237,147	26,307,000
Series B Convertible Preferred Stock
Preferred stock, par value	$ 0.001
Preferred stock, shares issued	17,000	43,000
Preferred stock, shares outstanding	17,430	43,000

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Collaboration revenue	$ 930	$ 2,031	$ 1,401	$ 4,404
Grant revenue	101	1,007	249	2,132
Service and license revenue	519	10	527	10
Total revenues	1,550	3,048	2,177	6,546
Operating expenses:
Research and development	19,686	23,639	41,906	36,870
General and administrative	5,098	4,085	9,957	8,242
Unoccupied facility expense		178		255
Total operating expenses	24,784	27,902	51,863	45,367
Loss from operations	(23,234)	(24,854)	(49,686)	(38,821)
Other income (expense):
Interest income	18	55	45	120
Interest expense	(263)		(510)
Other (loss) income, net	(112)	22	343	84
Net loss	$ (23,591)	$ (24,777)	$ (49,808)	$ (38,617)
Basic and diluted net loss per share	$ (0.80)	$ (0.94)	$ (1.70)	$ (1.47)
Weighted average shares used to compute basic and diluted net loss per share	29,335	26,286	29,230	26,286

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (23,591)	$ (24,777)	$ (49,808)	$ (38,617)
Other comprehensive income (loss):
Unrealized (loss) gain on marketable securities available-for-sale	(9)	1	(1)	70
Cumulative foreign currency translation adjustments	237	(97)	(1,057)	(106)
Total other comprehensive income (loss)	228	(96)	(1,058)	(36)
Total comprehensive loss	$ (23,363)	$ (24,873)	$ (50,866)	$ (38,653)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities
Net loss	$ (49,808)	$ (38,617)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	634	680
Gain on disposal of property and equipment		(24)
Accretion of discounts and amortization of premiums on marketable securities	314	500
Unoccupied facility expense		255
Accretion of debt discount related to debt financing	(100)
Accretion of end of term payment related to debt financing	107
Cash-settled portion of stock-based compensation expense	387
Stock compensation expense	3,872	2,946
Changes in operating assets and liabilities:
Accounts receivable	70	335
Prepaid expenses and other current assets	200	(3,603)
Restricted cash and other assets		(579)
Accounts payable	648	112
Accrued liabilities and other long term liabilities	(2,634)	3,217
Deferred revenues	(1,401)	996
Net cash used in operating activities	(47,711)	(33,782)
Investing activities
Purchases of marketable securities	(18,654)	(37,251)
Proceeds from maturities of marketable securities	34,585	65,794
Purchases of property and equipment, net	(1,668)	(919)
Net cash provided by investing activities	14,263	27,624
Financing activities
Proceeds from issuance of common stock, net	20,213
Proceeds from exercise of stock options and restricted stock awards	109	13
Proceeds from exercise of warrants	228
Proceeds from Employee Stock Purchase Plan	103	70
Net cash provided by financing activities	20,653	83
Effect of exchange rate changes on cash and cash equivalents	(230)	(15)
Net decrease in cash and cash equivalents	(13,025)	(6,090)
Cash and cash equivalents at beginning of period	49,511	23,122
Cash and cash equivalents at end of period	36,486	17,032
Non-cash investing and financing activities:
Cash paid during the year for interest	433
Disposal of fully depreciated property and equipment	4	664
Net change in unrealized gain on marketable securities	$ (1)	$ 70

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies Dynavax Technologies Corporation (“we,” “our,” “us,” “Dynavax” or the “Company”) is a clinical-stage biopharmaceutical company that uses toll-like receptor (“TLR”) biology to discover and develop novel vaccines and therapeutics. Our development programs are organized under our three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. We were incorporated in California in August 1996 under the name Double Helix Corporation, and we changed our name to Dynavax Technologies Corporation in September 1996. We reincorporated in Delaware in 2000. Basis of Presentation Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. In our opinion, these unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which we consider necessary to present fairly our financial position and the results of our operations and cash flows. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. Interim-period results are not necessarily indicative of results of operations or cash flows to be expected for a full-year period or any other interim-period. The condensed consolidated balance sheet at December 31, 2014, has been derived from audited financial statements at that date, but excludes disclosures required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements and these notes should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of Dynavax and our wholly-owned subsidiaries, Dynavax GmbH (formerly known as Rhein Biotech GmbH) and Dynavax International, B.V. Dynavax International, B.V. was dissolved in January 2015. All significant intercompany accounts and transactions, among consolidated entities, have been eliminated. We operate in one business segment: the discovery and development of biopharmaceutical products. Liquidity and Financial Condition We have incurred significant operating losses and negative cash flows from operations since our inception. As of June 30, 2015, we had cash, cash equivalents and marketable securities of $93.4 million. We currently estimate that we have sufficient cash resources to meet our anticipated cash needs through at least the next 12 months based on cash, cash equivalents and marketable securities on hand as of June 30, 2015 and anticipated revenues, funding from existing collaboration agreements and proceeds from financing arrangements. We expect to continue to spend substantial funds in connection with the development and manufacturing of our product candidates, particularly HEPLISAV-B^TMand our investigational cancer immunotherapeutic product candidate, SD-101, human clinical trials for our other product candidates and additional applications and advancement of our technology. In order to continue these activities, we may need to raise additional funds. This may occur through strategic collaboration and licensing arrangements and/or future public or private debt and equity financings. Sufficient additional funding may not be available on acceptable terms, or at all. If adequate funds are not available in the future, we may need to delay, reduce the scope of or put on hold the HEPLISAV-B program or our other development programs while we seek strategic alternatives. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from these estimates. Reverse Stock Split All references to numbers of shares of our common stock and per-share information in the accompanying financial statements have been adjusted retroactively to reflect the Company’s ten-for-one reverse stock split effected on November 7, 2014. The par value was not adjusted as a result of the reverse stock split. Summary of Significant Accounting Policies There have been no significant changes in our significant accounting policies during the six months ended June 30, 2015, as compared with those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014. Revenue Recognition Our revenues consist of amounts earned from collaborations, grants and fees from services and licenses. We enter into license and manufacturing agreements and collaborative research and development arrangements with pharmaceutical and biotechnology partners that may involve multiple deliverables. Our arrangements may include one or more of the following elements: upfront license payments, cost reimbursement for the performance of research and development activities, milestone payments, other contingent payments, contract manufacturing service fees, royalties and license fees. Each deliverable in the arrangement is evaluated to determine whether it meets the criteria to be accounted for as a separate unit of accounting or whether it should be combined with other deliverables. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the arrangement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. We recognize revenue when there is persuasive evidence that an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Non-refundable upfront fees received for license and collaborative agreements and other payments under collaboration agreements where we have continuing performance obligations related to the payments are deferred and recognized over our estimated performance period. Revenue is recognized on a ratable basis, unless we determine that another method is more appropriate, through the date at which our performance obligations are completed. Management makes its best estimate of the period over which we expect to fulfill our performance obligations, which may include clinical development activities. Given the uncertainties of research and development collaborations, significant judgment is required to determine the duration of the performance period. We recognize cost reimbursement revenue under collaborative agreements as the related research and development costs are incurred, as provided for under the terms of these agreements. Contingent consideration received for the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is defined as an event having all of the following characteristics: (i) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, (ii) the event can only be achieved based in whole or in part on either the entity’s performance or a specific outcome resulting from the entity’s performance and (iii) if achieved, the event would result in additional payments being due to the entity. Our license and collaboration agreements with our partners provide for payments to be paid to us upon the achievement of development milestones. Given the challenges inherent in developing biologic products, there is substantial uncertainty whether any such milestones will be achieved at the time we entered into these agreements. In addition, we evaluate whether the development milestones meet the criteria to be considered substantive. The conditions include: (i) the development work is contingent on either of the following: (a) the vendor’s performance to achieve the milestone or (b) the enhancement of the value of the deliverable item or items as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone; (ii) it relates solely to past performance and (iii) it is reasonable relative to all the deliverable and payment terms within the arrangement. As a result of our analysis, we may consider our development milestones to be substantive and, accordingly, we expect to recognize as revenue future payments received from such milestones as we achieve each milestone. Milestone payments that are contingent upon the achievement of substantive at-risk performance criteria are recognized in full upon achievement of those milestone events in accordance with the terms of the agreement and assuming all other revenue recognition criteria have been met. All revenue recognized to date under our collaborative agreements has been nonrefundable. Our license and collaboration agreements with certain partners also provide for contingent payments to be paid to us based solely upon the performance of our partner. For such contingent payments we expect to recognize the payments as revenue upon receipt, provided that collection is reasonably assured and the other revenue recognition criteria have been satisfied. Revenues from manufacturing agreements are recognized upon meeting revenue recognition criteria for substantial performance and acceptance by the customer. Revenue from royalty payments is contingent on future sales activities by our licensees. As a result, we recognize royalty revenue when all revenue recognition criteria have been satisfied. Revenue from government and private agency grants is recognized as the related research expenses are incurred and to the extent that funding is approved. Additionally, we recognize revenue based on the facilities and administrative cost rate reimbursable per the terms of the grant awards. Research and Development Expenses and Accruals Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed. We contract with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. Our accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. We may terminate these contracts upon written notice and we are generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be further responsible for termination fees and penalties. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company’s prior period accrued estimates for clinical trial activities through June 30, 2015. Recent Accounting Pronouncements Accounting Standards Update 2014-09 In May 2014, the FASB issued guidance codified in ASC 606, Revenue Recognition — Revenue from Contracts with Customers, which amends the guidance in former ASC 605, Revenue Recognition, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB deferred the effective date for annual reporting periods beginning after December 15, 2017 (including interim periods within those periods). Early adoption is permitted to the original effective date of December 15, 2016 (including interim periods within those periods). The Company is currently evaluating the impact of the provisions of ASC 606 on its financial statements. Accounting Standards Update 2014-15 In August 2014, the FASB issued guidance codified in ASC 205, Presentation of Financial Statements — Going Concern. Accounting Standards Update 2014-15 requires an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern and if those conditions exist, to make the required disclosures. The standard is effective for annual periods ending after December 15, 2016, and interim periods therein. The Company does not expect that the adoption of this standard will have a significant impact on its financial statements. Accounting Standards Update 2015-03 In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, which requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the corresponding debt liability rather than as an asset. This ASU will be effective for the Company in fiscal year 2016. Early adoption is permitted. The Company is currently assessing the future impact of this ASU on its financial statements.

Fair Value Measurements

6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurements

2. Fair Value Measurements

The Company measures fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

·	Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities;

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

·	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.

The carrying amounts of cash equivalents, accounts receivable, accounts payable and accrued liabilities are considered reasonable estimates of their respective fair value because of their short-term nature. The carrying amount of our long-term debt is considered a reasonable estimate of its respective fair value as it is amortized over its life using the effective interest rate.

Recurring Fair Value Measurements

The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis as of June 30, 2015 and December 31, 2014 (in thousands):

	Level 1		Level 2		Level 3		Total
June 30, 2015
Money market funds	$	30,847	$	-	$	-	$	30,847
U.S. government agency securities		-		56,895		-		56,895
Total	$	30,847	$	56,895	$	-	$	87,742

	Level 1		Level 2		Level 3		Total
December 31, 2014
Money market funds	$	46,989	$	-	$	-	$	46,989
U.S. government agency securities		-		73,141		-		73,141
Total	$	46,989	$	73,141	$	-	$	120,130

Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.

U.S. Government agency securities are measured at fair value using Level 2 inputs. We review trading activity and pricing for these investments as of each measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.

There were no transfers between Level 1 and Level 2 during the six months ended June 30, 2015.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Cash, Cash Equivalents and Marketable Securities

6 Months Ended

Jun. 30, 2015

Cash Cash Equivalents And Short Term Investments [Abstract]

Cash, Cash Equivalents and Marketable Securities

3. Cash, cash equivalents and marketable securities

The following is a summary of cash, cash equivalents and marketable securities available-for-sale as of June 30, 2015 and December 31, 2014 (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
June 30, 2015
Cash and cash equivalents:
Cash	$	5,639	$	-	$	-		$	5,639
Money market funds		30,847		-		-			30,847
Total cash and cash equivalents		36,486		-		-			36,486
Marketable securities available-for-sale:
U.S. government agency securities		56,895		7		(7	)		56,895
Total marketable securities available-for-sale		56,895		7		(7	)		56,895
Total cash, cash equivalents and marketable securities	$	93,381	$	7	$	(7	)	$	93,381
December 31, 2014
Cash and cash equivalents:
Cash	$	2,522	$	-	$	-		$	2,522
Money market funds		46,989		-		-			46,989
Total cash and cash equivalents		49,511		-		-			49,511
Marketable securities available-for-sale:
U.S. government agency securities		73,140		11		(10	)		73,141
Total marketable securities available-for-sale		73,140		11		(10	)		73,141
Total cash, cash equivalents and marketable securities	$	122,651	$	11	$	(10	)	$	122,652

The maturities of our marketable securities available-for-sale are as follows (in thousands):

	June 30, 2015
	Amortized Cost		Estimated Fair Value
Mature in one year or less	$	56,895	$	56,895
Mature after one year through two years		-		-
	$	56,895	$	56,895

All of our investments are classified as short-term and available-for-sale, as we may not hold our investments until maturity. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities, with unrealized gains and losses included in accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains and losses and declines in value, if any, judged to be other than temporary on available-for-sale securities are included in interest income or expense. The cost of securities sold is based on the specific identification method. Management assesses whether declines in the fair value of investment securities are other than temporary. In determining whether a decline is other than temporary, management considers the following factors:

·	Whether the investment has been in a continuous realized loss position for over 12 months;

·	the duration to maturity of our investments;

·	our intention and ability to hold the investments to maturity and if it is not more likely than not that we will be required to sell the investment before recovery of the amortized cost bases;

·	the credit rating, financial condition and near-term prospects of the issuer; and

·	the type of investments made.

To date, there have been no declines in fair value that have been identified as other than temporary.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2015

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

4. Commitments and Contingencies

We lease our facilities in Berkeley, California (“Berkeley Lease”) and Düsseldorf, Germany (“Düsseldorf Lease”) under operating leases that expire in June 2018 and March 2023, respectively. The Berkeley Lease provides for periods of escalating rent. The total cash payments over the life of the lease are divided by the total number of months in the lease period and the average rent is charged to expense each month during the lease period. We entered into sublease agreements under the Düsseldorf Lease for a certain portion of the leased space. The sublease income is offset against our rent expense.

During September 2013, we decided not to occupy a portion of our facility in Berkeley, California. As a result, we recorded an estimated unoccupied facility expense of $0.9 million during 2013, representing the present value of the rent payments and other costs associated with the lease, net of estimated sublease income, for the remaining life of the operating lease. During the first three quarters of 2014, we reassessed our timing and ability to sublet a portion of our facility and recorded a total unoccupied facility expense of $0.4 million for the year ended December 31, 2014. In December 2014, we decided to utilize the unoccupied portion of the facility and began to recognize rent expense under the terms noted in the Berkeley Lease.

Total net rent expense related to our operating leases for the three month periods ended June 30, 2015 and 2014, was $0.5 million and $0.4 million, respectively. Total net rent expense related to our operating leases for the six month periods ended June 30, 2015 and 2014, was $1.0 million and $0.9 million, respectively. Deferred rent was $0.5 million and $0.6 million as of June 30, 2015 and December 31, 2014, respectively.

Future minimum payments under the non-cancelable portion of our operating leases at June 30, 2015, excluding payments from sublease agreements, are as follows (in thousands):

Years ending December 31,
2015 (remaining)	$	1,144
2016		2,305
2017		2,354
2018		1,299
2019		474
Thereafter		1,540
Total	$	9,116

In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future events that cannot reasonably be estimated.

We rely on research institutions, contract research organizations, clinical investigators as well as clinical and commercial material manufacturers of our product candidates. As of June 30, 2015, under the terms of our agreements, including certain agreements relating to the ongoing Phase 3 trial of HEPLISAV-B, we are obligated to make future payments as services are provided of approximately $12.3 million through 2016. These agreements are terminable by us upon written notice. Generally, we are liable only for actual effort expended by the organizations at any point in time during the contract through the notice period.

From time to time, we are involved in claims, suits, and proceedings arising from the ordinary course of our business, including actions with respect to intellectual property claims, commercial claims, and other matters. Such claims, suits, and proceedings are inherently uncertain and their results cannot be predicted with certainty. Regardless of the outcome, such legal proceedings can have an adverse impact on us because of legal costs, diversion of management resources, and other factors. In addition, it is possible that a resolution of one or more such proceedings could result in substantial monetary damage awards, fines and penalties or orders requiring a change in our business practices, which could in the future materially and adversely affect our financial position, results of operations, or cash flows in a particular period.

Collaborative Research and Development Agreements

6 Months Ended

Jun. 30, 2015

Research And Development [Abstract]

Collaborative Research and Development Agreements

5. Collaborative Research and Development Agreements

AstraZeneca

In September 2006, we entered into a research collaboration and license agreement with AstraZeneca for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease.

In October 2011, we amended our agreement with AstraZeneca to provide that we will conduct initial clinical development of AZD1419 and AstraZeneca agreed to fund all program expenses to cover the cost of development activities through Phase 2a. Under the terms of the amended agreement, we received an initial payment of $3 million in 2011 to begin the clinical development program. We and AstraZeneca agreed to advance AZD1419 towards a Phase 1 clinical trial, which resulted in a development funding payment of $6 million received in the fourth quarter of 2012.

In January 2014, we amended our agreement with AstraZeneca for the clinical development of AZD1419 whereby responsibility for conducting clinical trials was transferred from Dynavax to AstraZeneca upon completion of the Phase 1 trial. In the first quarter of 2014, we received a $5.4 million payment that was due upon execution of this amendment.

The agreement with AstraZeneca has been amended several times including, most recently, in December 2014. Under the terms of this amendment, AstraZeneca will fully fund and Dynavax will conduct a Phase 2a safety and efficacy trial of AZD1419 in patients with asthma. In the fourth quarter of 2014, we received an $8.0 million payment due upon execution of this amendment, to be applied towards research and development expenses incurred in conducting the Phase 2a study.

Under the terms of this agreement, as amended, we are eligible to receive up to $100 million in additional milestone payments, based on the achievement of certain development and regulatory objectives. Additionally, upon commercialization, we are eligible to receive tiered royalties ranging from the mid to high single-digits based on product sales of any products originating from the collaboration. We have the option to co-promote in the United States products arising from the collaboration, if any. AstraZeneca has the right to sublicense its rights upon our prior consent.

Revenue from the $8.0 million payment received in the fourth quarter of 2014 was deferred and is being recognized as development work is performed, through December 2017. The $5.4 million payment received in the first quarter of 2014 and the $3.0 million initial payment received in 2011 were also deferred and are being recognized over the estimated remaining period of performance of development work, which is approximately 30 months.

The following table summarizes the revenues earned under our agreement with AstraZeneca, included as collaboration revenue in our consolidated statements of operations (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2015		2014		2015		2014
Initial payment	$	63	$	180	$	126	$	360
Subsequent payment		237		675		474		1,350
Performance of research activities		630		545		801		1,432
Total	$	930	$	1,400	$	1,401	$	3,142

As of June 30, 2015 and December 31, 2014, total deferred revenue from the initial payment, subsequent payment and development funding payments was $11.4 million and $12.8 million, respectively.

Absent early termination, the agreement will expire when all of AstraZeneca’s payment obligations expire. AstraZeneca has the right to terminate the agreement at any time upon prior written notice and either party may terminate the agreement early upon written notice if the other party commits an uncured material breach of the agreement.

National Institutes of Health (“NIH”) and Other Funding

We have been awarded various grants from the NIH and the NIH’s National Institute of Allergy and Infectious Disease (“NIAID”) in order to fund research. The awards are related to specific research objectives and we earn revenue as the related research expenses are incurred. We have earned revenue during the periods ended June 30, 2015 and 2014 from the following awards:

·	August 2014, NIH awarded us $0.2 million to fund research in developing a transgenic mouse model to study human TLR9 role in disease.

·	September 2013, NIH awarded us $0.2 million to fund research in developing TLR antagonists for therapy of hepatic fibrosis and cirrhosis.

·	June 2012, NIH awarded us $0.6 million to fund research in screening for inhibitors of TLR8 for treatment of autoimmune diseases.

·	May 2012, NIH awarded us $0.4 million to fund development of TLR8 inhibitors for treatment of rheumatoid arthritis.

August 2010, NIAID awarded us a grant to take a systems biology approach to study the differences between individuals who do or do not respond to vaccination against the hepatitis B virus. This study is one of several projects conducted under a grant to the Baylor Institute of Immunology Research in Dallas as part of the Human Immune Phenotyping Centers program. We have been awarded a total of $1.4 million under this grant.

·	September 2008, NIAID awarded us a five-year $17 million contract to develop our ISS technology using TLR9 agonists as vaccine adjuvants. The contract supports adjuvant development for anthrax as well as other disease models.

The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2015		2014		2015		2014
NIAID contracts	$	-	$	965	$	-	$	1,839
All other NIH contracts		101		42		249		293
Total grant revenue	$	101	$	1,007	$	249	$	2,132

Long-Term Debt

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Long-Term Debt

6.	Long-Term Debt

In December 2014, we entered into a Loan and Security Agreement (“Loan Agreement”) with Hercules Technology Growth Capital, Inc. (“Hercules”) under which we may borrow up to $40.0 million in two tranches.

We drew down the first tranche of $10.0 million upon closing of the transaction on December 23, 2014. The second tranche, of $30.0 million, can be drawn at our option any time prior to September 30, 2015, but only if we have achieved certain milestones relating to the ongoing HEPLISAV–B Phase 3 study (“Milestone A”). Milestone A was achieved in July 2015 as the Data and Safety Monitoring Board (“DSMB”) completed its third prespecified review and recommended that the study continue unchanged; however, no additional amounts were drawn down through the date of this quarterly report. We plan to use the proceeds received under the Loan Agreement to provide additional funding for HEPLISAV–B development and pre-commercialization activities, as a potential source of funding for clinical trials for our cancer immunotherapeutic product candidate, SD-101, and for general corporate purposes.

The interest rate for each tranche in the Loan Agreement is calculated at a rate equal to the greater of either: (i) 9.75% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.25%, and (ii) 9.75%. Payments under the Loan Agreement are interest only until February 1, 2016 (which will be extended until August 1, 2016, if we achieve Milestone A on or before September 30, 2015, and which will be extended until February 1, 2017, if we meet certain additional HEPLISAV-B Phase 3 related milestones (“Milestone B”) on or before August 1, 2016). The interest only period will be followed by equal monthly payments of principal and interest amortized over a 30 month schedule through the scheduled maturity date on July 1, 2018 (which would be extended through January 1, 2019 if we achieve Milestone A on or before September 30, 2015 or Milestone B on or before August 1, 2016) (the “Loan Maturity Date”). The entire principal balance, including a balloon payment of principal, as applicable, will be due and payable on the Loan Maturity Date, which we recorded as a liability and debt discount at the origination of the loan. See Note 10 for further information regarding our Loan Agreement.

A final payment equal to $840,000 (if an aggregate of $10.0 million is advanced under the Loan Agreement) or $2,400,000 (if an aggregate of $40.0 million is advanced under the Loan Agreement) will be due on the Loan Maturity Date, or such earlier date specified in the Loan Agreement. Our obligations under the Loan Agreement are secured by a security interest in substantially all of our assets, other than our intellectual property. Additionally, we paid a $400,000 facility charge to Hercules. The debt issuance costs and final payment fee are being amortized and accreted, respectively, to interest expense over the term of the term loan using the effective interest method.

In addition, under the Loan Agreement, Hercules was granted the right, at its discretion, to participate in any subsequent financing in an aggregate amount of up to $1,500,000 (that is, a maximum amount of $1,500,000 with respect to all subsequent financings collectively) on the same terms, conditions and pricing afforded to others participating in any such subsequent financing. Such right applies to subsequent financings in which the aggregate proceeds to us are at least $15 million.

The Loan Agreement includes customary affirmative and restrictive covenants, but does not include any financial maintenance covenants, and also includes standard events of default. At June 30, 2015, we were in compliance with all loan covenants. Upon an event of default, including a change of control, Hercules has the option to accelerate repayment of the loan, including payment of any applicable prepayment charges, which is 1.50% of the outstanding loan balance and accrued but unpaid interest.

As of June 30, 2015 and December 31, 2014, we had outstanding borrowings under the Loan Agreement of $10.0 million, with a carrying value of $9.5 million and $9.6 million, respectively, net of the debt discounts. The following table summarizes our outstanding future minimum payments associated with our long-term debt as of June 30, 2015 (in thousands):

Obligations:	Total		2015		2016-2017		2018-2019		2020 and Thereafter
Principal payments on long-term debt	$	10,000	$	-	$	7,425	$	2,575	$	-
Interest payments on long-term debt		1,910		496		1,328		86		-
Total	$	11,910	$	496	$	8,753	$	2,661	$	-

Net Loss Per Share	6 Months Ended
Net Loss Per Share	Jun. 30, 2015
Text Block [Abstract]
Net Loss Per Share	7. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period and giving effect to all potentially dilutive common shares using the treasury-stock method. For purposes of this calculation, common stock subject to repurchase by us, outstanding options, stock awards, Series B Convertible Preferred Stock, and warrants are considered to be potentially dilutive common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive. Stock options, Series B Convertible Preferred Stock, warrants and stock awards totaling approximately 4,660,000 and 7,630,000 shares of common stock as of June 30, 2015 and 2014, respectively, were excluded from the calculation of diluted net loss per share for the three months ended June 30, 2015 and 2014, because the effect of their inclusion would have been anti-dilutive. For periods in which the Company has a net loss and no instruments are determined to be dilutive, such as the three months ended June 30, 2015 and 2014, basic and diluted loss per share are the same.

Preferred Stock, Common Stock and Warrants	6 Months Ended
Preferred Stock, Common Stock and Warrants	Jun. 30, 2015
Preferred Stock Common Stock And Warrants [Abstract]
Preferred Stock, Common Stock and Warrants	8. Preferred Stock, Common Stock and Warrants Preferred Stock Outstanding As of June 30, 2015, there were 5,000,000 shares of preferred stock authorized and 17,430 shares of $0.001 par value Series B Convertible Preferred Stock outstanding. On February 26, 2015, 26,000 shares of our Series B Convertible Preferred Stock were converted into 2,600,000 shares of common stock. See Note 10 for further information regarding our Preferred Stock. Each share of Series B Convertible Preferred Stock is convertible into 100 shares of common stock at any time at the holder’s option. However, the holder is prohibited from converting the Series B Convertible Preferred Stock into shares of common stock if, as a result of such conversion, the holder and its affiliates would own more than 9.98% of the total number of shares of common stock then issued and outstanding. In the event of the Company’s liquidation, dissolution, or winding up, holders of Series B Convertible Preferred Stock will receive a payment equal to $0.001 per share before any proceeds are distributed to the common stockholders. Shares of Series B Convertible Preferred Stock generally have no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series B Convertible Preferred Stock is required to amend the terms of the Series B Convertible Preferred Stock. Holders of Series B Convertible Preferred Stock are not entitled to receive any dividends, unless and until specifically declared by the Company’s board of directors. The Series B Convertible Preferred Stock ranks senior to the Company’s common stock as to distributions of assets upon the Company’s liquidation, dissolution or winding up, whether voluntarily or involuntarily. The Series B Convertible Preferred Stock may rank senior to, on parity with or junior to any class or series of the Company’s capital stock created in the future depending upon the specific terms of such future stock issuance. Common Stock Outstanding As of June 30, 2015, the Company has 30,237,147 shares of common stock outstanding. On November 10, 2014, we entered into an At Market Issuance Sales Agreement (the “ATM Agreement”) with Cowen and Company, LLC (“Cowen”) under which we may offer and sell our common stock having aggregate sales proceeds of up to $50,000,000 from time to time through Cowen as our sales agent. Sales of our common stock through Cowen will be made by means of ordinary brokers’ transactions on the NASDAQ Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by us and Cowen. Cowen will use commercially reasonable efforts to sell our common stock from time to time, based upon instructions from us (including any price, time or size limits or other customary parameters or conditions we may impose). We agreed to pay Cowen a commission of up to 3.0% of the gross sales proceeds of any common stock sold through Cowen under the ATM Agreement. As of June 30, 2015, we had sold 929,590 shares of common stock under the ATM Agreement resulting in net proceeds to us of approximately $20.2 million. See Note 10 for further information regarding our Common Stock. Warrants As of June 30, 2015, no warrants to purchase shares of our common stock were outstanding. During the three months ended June 30, 2015, approximately 1,060,000 warrants were exercised resulting in the issuance of 375,000 shares of our common stock.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Equity Plans and Stock-Based Compensation

6 Months Ended

Jun. 30, 2015

Share Based Compensation [Abstract]

Equity Plans and Stock-Based Compensation

9. Equity Plans and Stock-Based Compensation

Option activity under our stock-based compensation plans during the six months ended June 30, 2015 was as follows (in thousands except per share amounts):

	Shares Underlying Outstanding Options (in thousands)			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Balance at December 31, 2014		1,820		$	27.48
Options granted		1,094			16.83
Options exercised		(8	)		15.60
Options cancelled:
Options forfeited (unvested)		(82	)		17.34
Options cancelled (vested)		(101	)		43.55
Balance at June 30, 2015		2,723			22.92		7.23	$	12,303
Vested and expected to vest at June 30, 2015		2,568			23.27		7.10	$	11,323
Exercisable at June 30, 2015		1,166			29.61		4.64	$	3,001

Restricted stock unit activity under our stock-based compensation plans during the six months ended June 30, 2015 was as follows (in thousands except per share amounts):

	Number of Shares (In thousands)			Weighted-Average Grant-Date Fair Value
Non-vested as of December 31, 2014		179		$	17.13
Granted		24		$	16.16
Vested		(3	)	$	16.90
Forfeited or expired		(5	)	$	18.71
Non-vested as of June 30, 2015		195		$	16.97

The aggregate intrinsic value of the restricted stock units outstanding as of June 30, 2015, based on our stock price on that date, was $4.6 million.

As of June 30, 2015, approximately 75,000 shares underlying stock options and restricted stock units awards with performance-based vesting criteria were outstanding. Vesting criteria for these performance-based awards have not been met as of June 30, 2015.

Under our stock-based compensation plans, option awards generally vest over a four-year period contingent upon continuous service and expire ten years from the date of grant (or earlier upon termination of continuous service). The fair value-based measurement of each option is estimated on the date of grant using the Black-Scholes option valuation model.

The fair value-based measurements and weighted-average assumptions used in the calculations of these measurements are as follows:

	Stock Options						Stock Options						Employee Stock Purchase Plan
	Three Months Ended						Six Months Ended						Six Months Ended
	June 30,						June 30,						June 30,
	2015			2014			2015			2014			2015			2014
Weighted-average fair value	$	14.28		$	13.60		$	12.76		$	15.50		$	8.18		$	9.20
Risk-free interest rate		1.7	%		1.9	%		1.7	%		1.8	%		0.4	%		0.2	%
Expected life (in years)		5.9			5.8			5.9			5.9			1.2			1.1
Volatility		0.7			1.3			0.7			1.4			0.7			0.9

We recognized stock-based compensation expense of $1.9 million and $1.7 million for the three months ended June 30, 2015 and 2014, respectively. We recognized stock-based compensation expense of $3.9 million and $2.9 million for the six months ended June 30, 2015 and 2014, respectively. The components of stock-based compensation expense were (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2015		2014		2015		2014
Research and development	$	868	$	738	$	1,753	$	1,430
General and administrative		1,050		938		2,119		1,516
Total	$	1,918	$	1,676	$	3,872	$	2,946

As of June 30, 2015, the total unrecognized compensation cost related to non-vested equity awards including all awards with time-based vesting amounted to $21.4 million, which is expected to be recognized over the remaining weighted-average vesting period of 3.0 years. Additionally, as of June 30, 2015, the total unrecognized compensation cost related to equity awards with performance-based vesting criteria not deemed probable of vesting amounted to $0.4 million.

Employee Stock Purchase Plan

As of June 30, 2015, 99,600 shares were approved for issuance under the 2004 Employee Stock Purchase Plan, subject to adjustment for a stock split, or any future stock dividend or other similar change in our common stock or capital structure. As of June 30, 2015, employees have acquired 94,410 shares of our common stock under the 2004 Employee Stock Purchase Plan. As of June 30, 2015, 5,190 shares of our common stock remained available for future purchases under the 2004 Employee Stock Purchase Plan.

In May 2014, stockholders of the Company approved the 2014 Employee Stock Purchase Plan (the “Purchase Plan”), pursuant to which the Company may issue up to 50,000 shares of its common stock, subject to adjustment, to its employees. The Purchase Plan provides for the purchase of common stock by eligible employees and became effective on May 28, 2014. The purchase price per share is the lesser of (i) 85% of the fair market value of the common stock on the commencement of the offer period (generally, the sixteenth day in February or August) or (ii) 85% of the fair market value of the common stock on the exercise date, which is the last day of a purchase period (generally, the fifteenth day in February or August). As of June 30, 2015, employees have acquired 7,959 shares of our common stock under the Purchase Plan and 42,041 shares of our common stock remained available for future purchases under the Purchase Plan.

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events In July 2015, we received additional cash of approximately $28.8 million resulting from sales of our common stock following the end of the quarter under our ATM Agreement. The ATM Agreement has concluded, as we have reached an aggregate of $50 million of gross proceeds from sales of our common stock as specified in the ATM Agreement. On July 9, 2015, we announced that the independent DSMB charged with periodically reviewing safety data from HBV-23, the ongoing Phase 3 clinical study of HEPLISAV-B, had completed its third prespecified review and recommended that the study continue unchanged, resulting in the achievement of Milestone A under the Loan Agreement with Hercules and providing us the option to draw down the $30.0 million second tranche at any time prior to September 30, 2015 pursuant to the agreement. No additional amount has been drawn down through the date of this quarterly report. Additionally, the loan amortization date is now August 1, 2016 and the Loan Maturity Date is now January 1, 2019. See Note 6 for terms disclosed under our Loan Agreement. On July 23, 2015, 17,430 shares of our Series B Convertible Preferred Stock were converted into 1,743,000 shares of common stock. As of July 23, 2015, no Series B Convertible Preferred Stock remained outstanding. On July 27, 2015, we completed an underwritten public offering of 5,227,273 shares of our common stock, including 681,818 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offered at a price to the public of $27.50 per share. The net proceeds to us from this offering were approximately $134.8 million, after deducting the underwriting discount and other estimated offering expenses payable by us. Subsequent events noted have been evaluated through the date of this quarterly report on Form 10-Q.

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. In our opinion, these unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which we consider necessary to present fairly our financial position and the results of our operations and cash flows. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. Interim-period results are not necessarily indicative of results of operations or cash flows to be expected for a full-year period or any other interim-period. The condensed consolidated balance sheet at December 31, 2014, has been derived from audited financial statements at that date, but excludes disclosures required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements and these notes should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of Dynavax and our wholly-owned subsidiaries, Dynavax GmbH (formerly known as Rhein Biotech GmbH) and Dynavax International, B.V. Dynavax International, B.V. was dissolved in January 2015. All significant intercompany accounts and transactions, among consolidated entities, have been eliminated. We operate in one business segment: the discovery and development of biopharmaceutical products.
Liquidity and Financial Condition	Liquidity and Financial Condition We have incurred significant operating losses and negative cash flows from operations since our inception. As of June 30, 2015, we had cash, cash equivalents and marketable securities of $93.4 million. We currently estimate that we have sufficient cash resources to meet our anticipated cash needs through at least the next 12 months based on cash, cash equivalents and marketable securities on hand as of June 30, 2015 and anticipated revenues, funding from existing collaboration agreements and proceeds from financing arrangements. We expect to continue to spend substantial funds in connection with the development and manufacturing of our product candidates, particularly HEPLISAV-B^TMand our investigational cancer immunotherapeutic product candidate, SD-101, human clinical trials for our other product candidates and additional applications and advancement of our technology. In order to continue these activities, we may need to raise additional funds. This may occur through strategic collaboration and licensing arrangements and/or future public or private debt and equity financings. Sufficient additional funding may not be available on acceptable terms, or at all. If adequate funds are not available in the future, we may need to delay, reduce the scope of or put on hold the HEPLISAV-B program or our other development programs while we seek strategic alternatives.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from these estimates.
Reverse Stock Split	Reverse Stock Split All references to numbers of shares of our common stock and per-share information in the accompanying financial statements have been adjusted retroactively to reflect the Company’s ten-for-one reverse stock split effected on November 7, 2014. The par value was not adjusted as a result of the reverse stock split.
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies There have been no significant changes in our significant accounting policies during the six months ended June 30, 2015, as compared with those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014.
Revenue Recognition	Revenue Recognition Our revenues consist of amounts earned from collaborations, grants and fees from services and licenses. We enter into license and manufacturing agreements and collaborative research and development arrangements with pharmaceutical and biotechnology partners that may involve multiple deliverables. Our arrangements may include one or more of the following elements: upfront license payments, cost reimbursement for the performance of research and development activities, milestone payments, other contingent payments, contract manufacturing service fees, royalties and license fees. Each deliverable in the arrangement is evaluated to determine whether it meets the criteria to be accounted for as a separate unit of accounting or whether it should be combined with other deliverables. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the arrangement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. We recognize revenue when there is persuasive evidence that an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Non-refundable upfront fees received for license and collaborative agreements and other payments under collaboration agreements where we have continuing performance obligations related to the payments are deferred and recognized over our estimated performance period. Revenue is recognized on a ratable basis, unless we determine that another method is more appropriate, through the date at which our performance obligations are completed. Management makes its best estimate of the period over which we expect to fulfill our performance obligations, which may include clinical development activities. Given the uncertainties of research and development collaborations, significant judgment is required to determine the duration of the performance period. We recognize cost reimbursement revenue under collaborative agreements as the related research and development costs are incurred, as provided for under the terms of these agreements. Contingent consideration received for the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is defined as an event having all of the following characteristics: (i) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, (ii) the event can only be achieved based in whole or in part on either the entity’s performance or a specific outcome resulting from the entity’s performance and (iii) if achieved, the event would result in additional payments being due to the entity. Our license and collaboration agreements with our partners provide for payments to be paid to us upon the achievement of development milestones. Given the challenges inherent in developing biologic products, there is substantial uncertainty whether any such milestones will be achieved at the time we entered into these agreements. In addition, we evaluate whether the development milestones meet the criteria to be considered substantive. The conditions include: (i) the development work is contingent on either of the following: (a) the vendor’s performance to achieve the milestone or (b) the enhancement of the value of the deliverable item or items as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone; (ii) it relates solely to past performance and (iii) it is reasonable relative to all the deliverable and payment terms within the arrangement. As a result of our analysis, we may consider our development milestones to be substantive and, accordingly, we expect to recognize as revenue future payments received from such milestones as we achieve each milestone. Milestone payments that are contingent upon the achievement of substantive at-risk performance criteria are recognized in full upon achievement of those milestone events in accordance with the terms of the agreement and assuming all other revenue recognition criteria have been met. All revenue recognized to date under our collaborative agreements has been nonrefundable. Our license and collaboration agreements with certain partners also provide for contingent payments to be paid to us based solely upon the performance of our partner. For such contingent payments we expect to recognize the payments as revenue upon receipt, provided that collection is reasonably assured and the other revenue recognition criteria have been satisfied. Revenues from manufacturing agreements are recognized upon meeting revenue recognition criteria for substantial performance and acceptance by the customer. Revenue from royalty payments is contingent on future sales activities by our licensees. As a result, we recognize royalty revenue when all revenue recognition criteria have been satisfied. Revenue from government and private agency grants is recognized as the related research expenses are incurred and to the extent that funding is approved. Additionally, we recognize revenue based on the facilities and administrative cost rate reimbursable per the terms of the grant awards.
Research and Development Expenses and Accruals	Research and Development Expenses and Accruals Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed. We contract with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. Our accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. We may terminate these contracts upon written notice and we are generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be further responsible for termination fees and penalties. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company’s prior period accrued estimates for clinical trial activities through June 30, 2015.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Standards Update 2014-09 In May 2014, the FASB issued guidance codified in ASC 606, Revenue Recognition — Revenue from Contracts with Customers, which amends the guidance in former ASC 605, Revenue Recognition, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB deferred the effective date for annual reporting periods beginning after December 15, 2017 (including interim periods within those periods). Early adoption is permitted to the original effective date of December 15, 2016 (including interim periods within those periods). The Company is currently evaluating the impact of the provisions of ASC 606 on its financial statements. Accounting Standards Update 2014-15 In August 2014, the FASB issued guidance codified in ASC 205, Presentation of Financial Statements — Going Concern. Accounting Standards Update 2014-15 requires an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern and if those conditions exist, to make the required disclosures. The standard is effective for annual periods ending after December 15, 2016, and interim periods therein. The Company does not expect that the adoption of this standard will have a significant impact on its financial statements. Accounting Standards Update 2015-03 In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, which requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the corresponding debt liability rather than as an asset. This ASU will be effective for the Company in fiscal year 2016. Early adoption is permitted. The Company is currently assessing the future impact of this ASU on its financial statements.

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Hierarchy for Financial Assets Measured at Fair Value on Recurring Basis

	Level 1		Level 2		Level 3		Total
June 30, 2015
Money market funds	$	30,847	$	-	$	-	$	30,847
U.S. government agency securities		-		56,895		-		56,895
Total	$	30,847	$	56,895	$	-	$	87,742

	Level 1		Level 2		Level 3		Total
December 31, 2014
Money market funds	$	46,989	$	-	$	-	$	46,989
U.S. government agency securities		-		73,141		-		73,141
Total	$	46,989	$	73,141	$	-	$	120,130

Cash, Cash Equivalents and Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2015

Cash Cash Equivalents And Short Term Investments [Abstract]

Summary of Cash, Cash Equivalents and Marketable Securities Available-for-Sale

The following is a summary of cash, cash equivalents and marketable securities available-for-sale as of June 30, 2015 and December 31, 2014 (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
June 30, 2015
Cash and cash equivalents:
Cash	$	5,639	$	-	$	-		$	5,639
Money market funds		30,847		-		-			30,847
Total cash and cash equivalents		36,486		-		-			36,486
Marketable securities available-for-sale:
U.S. government agency securities		56,895		7		(7	)		56,895
Total marketable securities available-for-sale		56,895		7		(7	)		56,895
Total cash, cash equivalents and marketable securities	$	93,381	$	7	$	(7	)	$	93,381
December 31, 2014
Cash and cash equivalents:
Cash	$	2,522	$	-	$	-		$	2,522
Money market funds		46,989		-		-			46,989
Total cash and cash equivalents		49,511		-		-			49,511
Marketable securities available-for-sale:
U.S. government agency securities		73,140		11		(10	)		73,141
Total marketable securities available-for-sale		73,140		11		(10	)		73,141
Total cash, cash equivalents and marketable securities	$	122,651	$	11	$	(10	)	$	122,652

Maturities of Marketable Securities Available-for-Sale

The maturities of our marketable securities available-for-sale are as follows (in thousands):

	June 30, 2015
	Amortized Cost		Estimated Fair Value
Mature in one year or less	$	56,895	$	56,895
Mature after one year through two years		-		-
	$	56,895	$	56,895

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2015

Commitments And Contingencies Disclosure [Abstract]

Future Minimum Payments Under Non-Cancelable Portion of Operating Leases

Future minimum payments under the non-cancelable portion of our operating leases at June 30, 2015, excluding payments from sublease agreements, are as follows (in thousands):

Years ending December 31,
2015 (remaining)	$	1,144
2016		2,305
2017		2,354
2018		1,299
2019		474
Thereafter		1,540
Total	$	9,116

Collaborative Research and Development Agreements (Tables)

6 Months Ended

Jun. 30, 2015

Astra Zeneca

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues earned under our agreement with AstraZeneca, included as collaboration revenue in our consolidated statements of operations (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2015		2014		2015		2014
Initial payment	$	63	$	180	$	126	$	360
Subsequent payment		237		675		474		1,350
Performance of research activities		630		545		801		1,432
Total	$	930	$	1,400	$	1,401	$	3,142

National Institutes of Health

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2015		2014		2015		2014
NIAID contracts	$	-	$	965	$	-	$	1,839
All other NIH contracts		101		42		249		293
Total grant revenue	$	101	$	1,007	$	249	$	2,132

Long-Term Debt (Tables)

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Schedule of Outstanding Future Minimum Payments of Long-Term Debt

The following table summarizes our outstanding future minimum payments associated with our long-term debt as of June 30, 2015 (in thousands):

Obligations:	Total		2015		2016-2017		2018-2019		2020 and Thereafter
Principal payments on long-term debt	$	10,000	$	-	$	7,425	$	2,575	$	-
Interest payments on long-term debt		1,910		496		1,328		86		-
Total	$	11,910	$	496	$	8,753	$	2,661	$	-

Equity Plans and Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2015

Share Based Compensation [Abstract]

Option Activity under Stock-Based Compensation Plans

Option activity under our stock-based compensation plans during the six months ended June 30, 2015 was as follows (in thousands except per share amounts):

	Shares Underlying Outstanding Options (in thousands)			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Balance at December 31, 2014		1,820		$	27.48
Options granted		1,094			16.83
Options exercised		(8	)		15.60
Options cancelled:
Options forfeited (unvested)		(82	)		17.34
Options cancelled (vested)		(101	)		43.55
Balance at June 30, 2015		2,723			22.92		7.23	$	12,303
Vested and expected to vest at June 30, 2015		2,568			23.27		7.10	$	11,323
Exercisable at June 30, 2015		1,166			29.61		4.64	$	3,001

Summary of Restricted Stock Units Activity

Restricted stock unit activity under our stock-based compensation plans during the six months ended June 30, 2015 was as follows (in thousands except per share amounts):

	Number of Shares (In thousands)			Weighted-Average Grant-Date Fair Value
Non-vested as of December 31, 2014		179		$	17.13
Granted		24		$	16.16
Vested		(3	)	$	16.90
Forfeited or expired		(5	)	$	18.71
Non-vested as of June 30, 2015		195		$	16.97

Fair Value-Based Measurements and Weighted-Average Assumptions

The fair value-based measurements and weighted-average assumptions used in the calculations of these measurements are as follows:

	Stock Options						Stock Options						Employee Stock Purchase Plan
	Three Months Ended						Six Months Ended						Six Months Ended
	June 30,						June 30,						June 30,
	2015			2014			2015			2014			2015			2014
Weighted-average fair value	$	14.28		$	13.60		$	12.76		$	15.50		$	8.18		$	9.20
Risk-free interest rate		1.7	%		1.9	%		1.7	%		1.8	%		0.4	%		0.2	%
Expected life (in years)		5.9			5.8			5.9			5.9			1.2			1.1
Volatility		0.7			1.3			0.7			1.4			0.7			0.9

Stock-Based Compensation Expense

The components of stock-based compensation expense were (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2015		2014		2015		2014
Research and development	$	868	$	738	$	1,753	$	1,430
General and administrative		1,050		938		2,119		1,516
Total	$	1,918	$	1,676	$	3,872	$	2,946

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2015 USD ($) Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of operating segment \| Segment	1
Cash, cash equivalents and marketable securities \| $	$ 93.4
Reverse stock split	ten-for-one
Reverse stock split effective date	Nov. 07, 2014

- Definition

Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.

+ References + Details

Fair Value Hierarchy for Financial Assets Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	$ 87,742	$ 120,130
Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	30,847	46,989
Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	56,895	73,141
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	30,847	46,989
Money Market Funds \| Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	30,847	46,989
U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	56,895	73,141
U.S. Government Agency Securities \| Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets	$ 56,895	$ 73,141

Fair Value Measurements - Additional Information (Detail)	Jun. 30, 2015 USD ($)
Fair Value Disclosures [Abstract]
Transfers between level 1 and level 2	$ 0

Summary of Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	$ 93,381	$ 122,651
Unrealized Gains	7	11
Unrealized Losses	(7)	(10)
Estimated Fair Value	93,381	122,652
Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	36,486	49,511
Estimated Fair Value	36,486	49,511
Marketable Securities Available-for-Sale
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	56,895	73,140
Unrealized Gains	7	11
Unrealized Losses	(7)	(10)
Estimated Fair Value	56,895	73,141
Cash \| Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	5,639	2,522
Estimated Fair Value	5,639	2,522
Money Market Funds \| Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	30,847	46,989
Estimated Fair Value	30,847	46,989
U.S. Government Agency Securities \| Marketable Securities Available-for-Sale
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	56,895	73,140
Unrealized Gains	7	11
Unrealized Losses	(7)	(10)
Estimated Fair Value	$ 56,895	$ 73,141

Summary of Amortized Cost and Estimated Fair Value of Marketable Securities Available-for-Sale (Detail) $ in Thousands	Jun. 30, 2015 USD ($)
Amortized Cost
Mature in one year or less	$ 56,895
Mature after one year through two years	0
Total amortized cost	56,895
Estimated Fair Value
Mature in one year or less	56,895
Mature after one year through two years	0
Total estimated fair value	$ 56,895

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Loss Contingencies [Line Items]
Unoccupied facility expense		$ 178		$ 255
Rent expense, net	$ 500	$ 400	$ 1,000	$ 900
Deferred rent	$ 500		500		$ 600
Future payments obligation			$ 12,300
Berkeley, California (the "Berkeley Lease")
Loss Contingencies [Line Items]
Operating leases expiration date			2018-06
Unoccupied facility expense					$ 400	$ 900
Dusseldorf, Germany (the "Dusseldorf Lease")
Loss Contingencies [Line Items]
Operating leases expiration date			2023-03

Future Minimum Payments Under Non-Cancelable Portion of Operating Leases (Detail) $ in Thousands	Jun. 30, 2015 USD ($)
Commitments And Contingencies Disclosure [Abstract]
2015 (remaining)	$ 1,144
2016	2,305
2017	2,354
2018	1,299
2019	474
Thereafter	1,540
Total	$ 9,116

Collaborative Research and Development Agreements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended			6 Months Ended	12 Months Ended
	Oct. 31, 2011	Sep. 30, 2008	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2012	Jun. 30, 2015	Dec. 31, 2011	Aug. 31, 2014	Sep. 30, 2013	Jun. 30, 2012	May 31, 2012	Aug. 31, 2010
Deferred Revenue Arrangement [Line Items]
Revenue from milestone payment			$ 8,000,000	$ 5,400,000			$ 3,000,000
Astra Zeneca
Deferred Revenue Arrangement [Line Items]
Collaboration Revenue	$ 3,000,000
Deferred revenue recognition period							30 days
Deferred revenue			12,800,000			$ 11,400,000
National Institutes of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable								$ 200,000
National Institutes of Health \| Hepatic Fibrosis and Cirrhosis
Deferred Revenue Arrangement [Line Items]
Grants receivable									$ 200,000
National Institutes of Health \| Autoimmune Disease
Deferred Revenue Arrangement [Line Items]
Grants receivable										$ 600,000
National Institutes of Health \| Rheumatoid Arthritis
Deferred Revenue Arrangement [Line Items]
Grants receivable											$ 400,000
National Institute of Allergy and Infectious Diseases \| Hepatitis B Virus
Deferred Revenue Arrangement [Line Items]
Grants receivable												$ 1,400,000
National Institute of Allergy and Infectious Diseases \| Iss Technology
Deferred Revenue Arrangement [Line Items]
Research collaboration and license agreement period		5 years
Grants receivable		$ 17,000,000
Amendment
Deferred Revenue Arrangement [Line Items]
Collaboration Revenue			$ 8,000,000	$ 5,400,000	$ 6,000,000
Amendment \| Maximum
Deferred Revenue Arrangement [Line Items]
Additional revenue recognized						$ 100,000,000

Summary of Revenue Recognized under Various Agreements (Detail) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2011
Product Information [Line Items]
Performance of research activities		$ 8,000		$ 5,400			$ 3,000
Total revenues	$ 1,550		$ 3,048		$ 2,177	$ 6,546
Grant revenue	101		1,007		249	2,132
National Institute of Allergy and Infectious Diseases
Product Information [Line Items]
Grant revenue			965			1,839
National Institutes of Health
Product Information [Line Items]
Grant revenue	101		42		249	293
Astra Zeneca
Product Information [Line Items]
Initial payment	63		180		126	360
Subsequent payment	237		675		474	1,350
Performance of research activities	630		545		801	1,432
Total revenues	$ 930		$ 1,400		$ 1,401	$ 3,142

Long-Term Debt - Additional Information (Detail)		3 Months Ended	6 Months Ended
Long-Term Debt - Additional Information (Detail)	Dec. 23, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Sep. 30, 2015 USD ($)	Dec. 31, 2014 USD ($) TRANCHES
Debt Instrument [Line Items]
Advance payment on loan agreement			$ 40,000,000
Facility charge to Hercules			400,000
First Tranche
Debt Instrument [Line Items]
Final minimum repayment of debt		$ 840,000	840,000
Advance payment on loan agreement			10,000,000
Hercules Technology Growth Capital, Inc. (“Hercules”)
Debt Instrument [Line Items]
Maximum borrowing capacity		1,500,000	$ 1,500,000		$ 40,000,000
Number of tranches for loan and security agreement \| TRANCHES					2
Proceeds from lines of credit		$ 0
Debt instrument, interest rate		9.75%	9.75%
Debt instrument, interest rate terms			The interest rate for each tranche in the Loan Agreement is calculated at a rate equal to the greater of either: (i) 9.75% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.25%, and (ii) 9.75%
Debt instrument, payment terms			Payments under the Loan Agreement are interest only until February 1, 2016 (which will be extended until August 1, 2016, if we achieve Milestone A on or before September 30, 2015, and which will be extended until February 1, 2017, if we meet certain additional HEPLISAV-B Phase 3 related milestones (“Milestone B”) on or before August 1, 2016). The interest only period will be followed by equal monthly payments of principal and interest amortized over a 30 month schedule through the scheduled maturity date on July 1, 2018 (which would be extended through January 1, 2019 if we achieve Milestone A on or before September 30, 2015 or Milestone B on or before August 1, 2016) (the “Loan Maturity Date”).
Debt instrument, maturity date			Jul. 01, 2018
Debt instrument, extension date			Jan. 01, 2019
Final minimum repayment of debt		$ 2,400,000	$ 2,400,000
Debt instrument prepayment charge			1.50%
Outstanding borrowings		10,000,000	$ 10,000,000		$ 10,000,000
Carrying value debt		$ 9,500,000	9,500,000		$ 9,600,000
Hercules Technology Growth Capital, Inc. (“Hercules”) \| Minimum
Debt Instrument [Line Items]
Proceeds from lines of credit			$ 15,000,000
Hercules Technology Growth Capital, Inc. (“Hercules”) \| Prime Rate
Debt Instrument [Line Items]
Debt instrument, interest rate		9.75%	9.75%
Debt instrument, basis spread on variable rate			5.25%
Hercules Technology Growth Capital, Inc. (“Hercules”) \| First Tranche
Debt Instrument [Line Items]
Proceeds from lines of credit	$ 10,000,000
Hercules Technology Growth Capital, Inc. (“Hercules”) \| Second Tranche
Debt Instrument [Line Items]
Proceeds from lines of credit		$ 0
Hercules Technology Growth Capital, Inc. (“Hercules”) \| Second Tranche \| Scenario Forecast
Debt Instrument [Line Items]
Debt under Loan Agreement				$ 30,000,000
Debt instrument, maturity date			Jan. 01, 2019

Schedule of Outstanding Future Minimum Payments of Long-Term Debt (Detail) $ in Thousands	Jun. 30, 2015 USD ($)
Debt Instrument [Line Items]
Total	$ 11,910
2015	496
2016-2017	8,753
2018-2019	2,661
Principal payments on long-term debt
Debt Instrument [Line Items]
Total	10,000
2016-2017	7,425
2018-2019	2,575
Interest payments on long-term debt
Debt Instrument [Line Items]
Total	1,910
2015	496
2016-2017	1,328
2018-2019	$ 86

Net Loss Per Share - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share [Abstract]
Stock options, Series B Convertible Preferred Stock, warrants and stock awards excluding calculation of diluted net loss per share			4,660,000	7,630,000
Dilutive securities, effect on basic earnings per share	$ 0	$ 0

Preferred Stock, Common Stock and Warrants - Additional Information (Detail)			6 Months Ended
	Feb. 26, 2015 shares	Nov. 10, 2014 USD ($)	Jun. 30, 2015 USD ($) $ / shares shares	Dec. 31, 2014 $ / shares shares
Class Of Stock [Line Items]
Preferred stock, shares authorized			5,000,000	5,000,000
Preferred stock, par value \| $ / shares			$ 0.001	$ 0.001
Common stock, shares outstanding			30,237,147	26,307,000
Proceeds from issuance of common stock, net \| $			$ 20,213,000
Warrants to purchase common stock			0
Number of warrants exercised during period			1,060,000
Cowen
Class Of Stock [Line Items]
Issuance of common stock, (in shares)			929,590
Proceeds from issuance of common stock, net \| $			$ 20,200,000
Maximum \| Cowen
Class Of Stock [Line Items]
Common stock sales agreement aggregate sales proceeds \| $		$ 50,000,000
Commission on gross sales proceeds of common stock		3.00%
Common Stock
Class Of Stock [Line Items]
Convertible common stock shares	2,600,000
Warrant
Class Of Stock [Line Items]
Issuance of common stock, (in shares)			375,000
Series B Convertible Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares outstanding			17,430	43,000
Preferred stock, par value \| $ / shares			$ 0.001
Convertible common stock shares	26,000
Convertible common stock shares			0.01
Conversion of stock, shares converted			100
Convertible preferred stock, terms of conversion			The holder is prohibited from converting the Series B Convertible Preferred Stock into shares of common stock if, as a result of such conversion, the holder and its affiliates would own more than 9.98% of the total number of shares of common stock then issued and outstanding.
Convertible preferred stock, settlement terms			In the event of the Company’s liquidation, dissolution, or winding up, holders of Series B Convertible Preferred Stock will receive a payment equal to $0.001 per share before any proceeds are distributed to the common stockholders.
Series B Convertible Preferred Stock
Class Of Stock [Line Items]
Maximum percentage of shares of common stock issued and outstanding from conversion of preferred stock			9.98%

Option Activity under Stock Plans (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2015 USD ($) $ / shares shares
Number of Options Outstanding
Beginning balance \| shares	1,820
Options granted \| shares	1,094
Options exercised \| shares	(8)
Ending balance \| shares	2,723
Vested and expected to vest at end of period \| shares	2,568
Exercisable at end of period \| shares	1,166
Weighted-Average Price Per Share
Beginning balance \| $ / shares	$ 27.48
Options granted \| $ / shares	16.83
Options exercised \| $ / shares	15.60
Ending balance \| $ / shares	22.92
Vested and expected to vest at end of period \| $ / shares	23.27
Exercisable at end of period \| $ / shares	$ 29.61
Weighted Average Remaining Contractual Life (In years)
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	7 years 2 months 23 days
Outstanding options vested and expected to vest at end of period	7 years 1 month 6 days
Options exercisable at end of period	4 years 7 months 21 days
Aggregate Intrinsic Value
Balance at June 30, 2015 \| $	$ 12,303
Outstanding options (vested and expected to vest) at end of period \| $	11,323
Options exercisable at end of period \| $	$ 3,001
Unvested
Number of Options Outstanding
Options cancelled \| shares	(82)
Weighted-Average Price Per Share
Options cancelled \| $ / shares	$ 17.34
Vested
Number of Options Outstanding
Options cancelled \| shares	(101)
Weighted-Average Price Per Share
Options cancelled \| $ / shares	$ 43.55

Summary of Restricted Stock Units Activity (Detail) - Restricted Stock Units (RSUs) shares in Thousands	6 Months Ended
	Jun. 30, 2015 $ / shares shares
Number of shares
Beginning Balance \| shares	179
Granted \| shares	24
Vested \| shares	(3)
Forfeited or expired \| shares	(5)
Ending Balance \| shares	195
Weighted Average Grant Date Fair Value
Beginning Balance \| $ / shares	$ 17.13
Granted \| $ / shares	16.16
Vested \| $ / shares	16.90
Forfeited or expired \| $ / shares	18.71
Ending Balance \| $ / shares	$ 16.97

Equity Plans and Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	May 31, 2014	Jan. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting period					4 years
Expiration period					10 years
Stock-based compensation expense			$ 1,918	$ 1,676	$ 3,872	$ 2,946
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved and approved for issuance			99,600		99,600
Shares issued to employees	50,000				94,410
Shares remaining available for future purchases			5,190		5,190
Employee Stock Purchase Plan \| The commencement of the offer period (generally, the sixteenth day in February or August
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price per share as percentage of fair market value of common stock		85.00%
Employee Stock Purchase Plan \| The exercise date, which is the last day of a purchase period (generally, the fifteenth day in February or August)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price per share as percentage of fair market value of common stock		85.00%
2014 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued to employees					7,959
Shares remaining available for future purchases			42,041		42,041
Time Based Vesting Schedule
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested equity awards			$ 21,400		$ 21,400
Total unrecognized compensation cost, weighted-average vesting period					3 years
Performance Based Vesting Schedule
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested equity awards			400		$ 400
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate intrinsic value			$ 4,600		$ 4,600
Performance based Vesting Condition
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares underlying stock options and restricted stock units awards with performance-based vesting criteria			75,000		75,000

Fair Value-Based Measurements and Weighted-Average Assumptions (Detail) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average fair value			$ 8.18	$ 9.20
Risk-free interest rate			0.40%	0.20%
Expected life (in years)			1 year 2 months 12 days	1 year 1 month 6 days
Volatility			0.70%	0.90%
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average fair value	$ 14.28	$ 13.60	$ 12.76	$ 15.50
Risk-free interest rate	1.70%	1.90%	1.70%	1.80%
Expected life (in years)	5 years 10 months 24 days	5 years 9 months 18 days	5 years 10 months 24 days	5 years 10 months 24 days
Volatility	0.70%	1.30%	0.70%	1.40%

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	$ 1,918	$ 1,676	$ 3,872	$ 2,946
Research and Development Expense
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	868	738	1,753	1,430
General and Administrative Expense
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	$ 1,050	$ 938	$ 2,119	$ 1,516

Subsequent Event - Additional Information (Detail) - USD ($)				1 Months Ended	3 Months Ended	6 Months Ended
	Jul. 27, 2015	Jul. 23, 2015	Feb. 26, 2015	Jul. 31, 2015	Jun. 30, 2015	Jun. 30, 2015	Sep. 30, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Proceeds from issuance of common stock						$ 20,213,000
Series B Convertible Preferred Stock
Subsequent Event [Line Items]
Convertible common stock shares			26,000
Common shares issued upon conversion of convertible preferred stocks					100	100
Preferred stock, shares outstanding					17,430	17,430		43,000
Cowen
Subsequent Event [Line Items]
Proceeds from issuance of common stock						$ 20,200,000
Common shares issued in initial public offering						929,590
Hercules Technology Growth Capital, Inc. (“Hercules”)
Subsequent Event [Line Items]
Proceeds from lines of credit					$ 0
Debt instrument, maturity date						Jul. 01, 2018
Hercules Technology Growth Capital, Inc. (“Hercules”) \| Second Tranche
Subsequent Event [Line Items]
Proceeds from lines of credit					$ 0
Hercules Technology Growth Capital, Inc. (“Hercules”) \| Second Tranche \| Scenario Forecast
Subsequent Event [Line Items]
Debt under Loan Agreement							$ 30,000,000
Debt instrument, maturity date						Jan. 01, 2019
Subsequent Event \| Common Stock
Subsequent Event [Line Items]
Common shares issued upon conversion of convertible preferred stocks		1,743,000
Subsequent Event \| Common Stock \| I P O
Subsequent Event [Line Items]
Common shares issued in initial public offering	5,227,273
Public offering net price per share	$ 27.50
Net proceeds from offering	$ 134,800,000
Subsequent Event \| Common Stock \| Over-Allotment Option
Subsequent Event [Line Items]
Common shares issued in initial public offering	681,818
Subsequent Event \| Series B Convertible Preferred Stock
Subsequent Event [Line Items]
Convertible common stock shares		17,430
Preferred stock, shares outstanding		0
Subsequent Event \| Cowen
Subsequent Event [Line Items]
Proceeds from issuance of common stock				$ 28,800,000
Common stock sales agreement aggregate sales proceeds to date				$ 50,000,000